Detectable end of radiation prostate specific antigen assists in identifying men with unfavorable intermediate-risk prostate cancer at high risk of distant recurrence and cancer-specific mortality

Publication Date:
2018-03-09
Publisher:
Wiley-Blackwell
Print ISSN:
0270-4137
Electronic ISSN:
1097-0045
Topics:
Medicine
Published by:
http://www.wiley.com/wiley-blackwell
_version_ 1839207948161646592
autor Jonathan Hayman, Ryan Phillips, Di Chen, Jamie Perin, Amol K. Narang, Janson Trieu, Noura Radwan, Stephen Greco, Curtiland Deville, Todd McNutt, Daniel Y. Song, Theodore L. De; Weese, Phuoc T. Tran
beschreibung Background Undetectable End of Radiation PSA (EOR-PSA) has been shown to predict improved survival in prostate cancer (PCa). While validating the unfavorable intermediate-risk (UIR) and favorable intermediate-risk (FIR) stratifications among Johns Hopkins PCa patients treated with radiotherapy, we examined whether EOR-PSA could further risk stratify UIR men for survival. Methods A total of 302 IR patients were identified in the Johns Hopkins PCa database (178 UIR, 124 FIR). Kaplan-Meier curves and multivariable analysis was performed via Cox regression for biochemical recurrence free survival (bRFS), distant metastasis free survival (DMFS), and overall survival (OS), while a competing risks model was used for PCa specific survival (PCSS). Among the 235 patients with known EOR-PSA values, we then stratified by EOR-PSA and performed the aforementioned analysis. Results The median follow-up time was 11.5 years (138 months). UIR was predictive of worse DMFS and PCSS ( P  = 0.008 and P  = 0.023) on multivariable analysis (MVA). Increased radiation dose was significant for improved DMFS ( P  = 0.016) on MVA. EOR-PSA was excluded from the models because it did not trend towards significance as a continuous or binary variable due to interaction with UIR, and we were unable to converge a multivariable model with a variable to control for this interaction. However, when stratifying by detectable versus undetectable EOR-PSA, UIR had worse DMFS and PCSS among detectable EOR-PSA patients, but not undetectable patients. UIR was significant on MVA among detectable EOR-PSA patients for DMFS ( P  = 0.021) and PCSS ( P  = 0.033), while RT dose also predicted PCSS ( P  = 0.013). Conclusions EOR-PSA can assist in predicting DMFS and PCSS among UIR patients, suggesting a clinically meaningful time point for considering intensification of treatment in clinical trials of intermediate-risk men.
citation_standardnr 6200611
datenlieferant ipn_articles
feed_id 1901
feed_publisher Wiley-Blackwell
feed_publisher_url http://www.wiley.com/wiley-blackwell
insertion_date 2018-03-09
journaleissn 1097-0045
journalissn 0270-4137
publikationsjahr_anzeige 2018
publikationsjahr_facette 2018
publikationsjahr_intervall 7984:2015-2019
publikationsjahr_sort 2018
publisher Wiley-Blackwell
quelle Prostate
relation http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fpros.23507
search_space articles
shingle_author_1 Jonathan Hayman, Ryan Phillips, Di Chen, Jamie Perin, Amol K. Narang, Janson Trieu, Noura Radwan, Stephen Greco, Curtiland Deville, Todd McNutt, Daniel Y. Song, Theodore L. De; Weese, Phuoc T. Tran
shingle_author_2 Jonathan Hayman, Ryan Phillips, Di Chen, Jamie Perin, Amol K. Narang, Janson Trieu, Noura Radwan, Stephen Greco, Curtiland Deville, Todd McNutt, Daniel Y. Song, Theodore L. De; Weese, Phuoc T. Tran
shingle_author_3 Jonathan Hayman, Ryan Phillips, Di Chen, Jamie Perin, Amol K. Narang, Janson Trieu, Noura Radwan, Stephen Greco, Curtiland Deville, Todd McNutt, Daniel Y. Song, Theodore L. De; Weese, Phuoc T. Tran
shingle_author_4 Jonathan Hayman, Ryan Phillips, Di Chen, Jamie Perin, Amol K. Narang, Janson Trieu, Noura Radwan, Stephen Greco, Curtiland Deville, Todd McNutt, Daniel Y. Song, Theodore L. De; Weese, Phuoc T. Tran
shingle_catch_all_1 Detectable end of radiation prostate specific antigen assists in identifying men with unfavorable intermediate-risk prostate cancer at high risk of distant recurrence and cancer-specific mortality
Background Undetectable End of Radiation PSA (EOR-PSA) has been shown to predict improved survival in prostate cancer (PCa). While validating the unfavorable intermediate-risk (UIR) and favorable intermediate-risk (FIR) stratifications among Johns Hopkins PCa patients treated with radiotherapy, we examined whether EOR-PSA could further risk stratify UIR men for survival. Methods A total of 302 IR patients were identified in the Johns Hopkins PCa database (178 UIR, 124 FIR). Kaplan-Meier curves and multivariable analysis was performed via Cox regression for biochemical recurrence free survival (bRFS), distant metastasis free survival (DMFS), and overall survival (OS), while a competing risks model was used for PCa specific survival (PCSS). Among the 235 patients with known EOR-PSA values, we then stratified by EOR-PSA and performed the aforementioned analysis. Results The median follow-up time was 11.5 years (138 months). UIR was predictive of worse DMFS and PCSS ( P  = 0.008 and P  = 0.023) on multivariable analysis (MVA). Increased radiation dose was significant for improved DMFS ( P  = 0.016) on MVA. EOR-PSA was excluded from the models because it did not trend towards significance as a continuous or binary variable due to interaction with UIR, and we were unable to converge a multivariable model with a variable to control for this interaction. However, when stratifying by detectable versus undetectable EOR-PSA, UIR had worse DMFS and PCSS among detectable EOR-PSA patients, but not undetectable patients. UIR was significant on MVA among detectable EOR-PSA patients for DMFS ( P  = 0.021) and PCSS ( P  = 0.033), while RT dose also predicted PCSS ( P  = 0.013). Conclusions EOR-PSA can assist in predicting DMFS and PCSS among UIR patients, suggesting a clinically meaningful time point for considering intensification of treatment in clinical trials of intermediate-risk men.
Jonathan Hayman, Ryan Phillips, Di Chen, Jamie Perin, Amol K. Narang, Janson Trieu, Noura Radwan, Stephen Greco, Curtiland Deville, Todd McNutt, Daniel Y. Song, Theodore L. De; Weese, Phuoc T. Tran
Wiley-Blackwell
0270-4137
02704137
1097-0045
10970045
shingle_catch_all_2 Detectable end of radiation prostate specific antigen assists in identifying men with unfavorable intermediate-risk prostate cancer at high risk of distant recurrence and cancer-specific mortality
Background Undetectable End of Radiation PSA (EOR-PSA) has been shown to predict improved survival in prostate cancer (PCa). While validating the unfavorable intermediate-risk (UIR) and favorable intermediate-risk (FIR) stratifications among Johns Hopkins PCa patients treated with radiotherapy, we examined whether EOR-PSA could further risk stratify UIR men for survival. Methods A total of 302 IR patients were identified in the Johns Hopkins PCa database (178 UIR, 124 FIR). Kaplan-Meier curves and multivariable analysis was performed via Cox regression for biochemical recurrence free survival (bRFS), distant metastasis free survival (DMFS), and overall survival (OS), while a competing risks model was used for PCa specific survival (PCSS). Among the 235 patients with known EOR-PSA values, we then stratified by EOR-PSA and performed the aforementioned analysis. Results The median follow-up time was 11.5 years (138 months). UIR was predictive of worse DMFS and PCSS ( P  = 0.008 and P  = 0.023) on multivariable analysis (MVA). Increased radiation dose was significant for improved DMFS ( P  = 0.016) on MVA. EOR-PSA was excluded from the models because it did not trend towards significance as a continuous or binary variable due to interaction with UIR, and we were unable to converge a multivariable model with a variable to control for this interaction. However, when stratifying by detectable versus undetectable EOR-PSA, UIR had worse DMFS and PCSS among detectable EOR-PSA patients, but not undetectable patients. UIR was significant on MVA among detectable EOR-PSA patients for DMFS ( P  = 0.021) and PCSS ( P  = 0.033), while RT dose also predicted PCSS ( P  = 0.013). Conclusions EOR-PSA can assist in predicting DMFS and PCSS among UIR patients, suggesting a clinically meaningful time point for considering intensification of treatment in clinical trials of intermediate-risk men.
Jonathan Hayman, Ryan Phillips, Di Chen, Jamie Perin, Amol K. Narang, Janson Trieu, Noura Radwan, Stephen Greco, Curtiland Deville, Todd McNutt, Daniel Y. Song, Theodore L. De; Weese, Phuoc T. Tran
Wiley-Blackwell
0270-4137
02704137
1097-0045
10970045
shingle_catch_all_3 Detectable end of radiation prostate specific antigen assists in identifying men with unfavorable intermediate-risk prostate cancer at high risk of distant recurrence and cancer-specific mortality
Background Undetectable End of Radiation PSA (EOR-PSA) has been shown to predict improved survival in prostate cancer (PCa). While validating the unfavorable intermediate-risk (UIR) and favorable intermediate-risk (FIR) stratifications among Johns Hopkins PCa patients treated with radiotherapy, we examined whether EOR-PSA could further risk stratify UIR men for survival. Methods A total of 302 IR patients were identified in the Johns Hopkins PCa database (178 UIR, 124 FIR). Kaplan-Meier curves and multivariable analysis was performed via Cox regression for biochemical recurrence free survival (bRFS), distant metastasis free survival (DMFS), and overall survival (OS), while a competing risks model was used for PCa specific survival (PCSS). Among the 235 patients with known EOR-PSA values, we then stratified by EOR-PSA and performed the aforementioned analysis. Results The median follow-up time was 11.5 years (138 months). UIR was predictive of worse DMFS and PCSS ( P  = 0.008 and P  = 0.023) on multivariable analysis (MVA). Increased radiation dose was significant for improved DMFS ( P  = 0.016) on MVA. EOR-PSA was excluded from the models because it did not trend towards significance as a continuous or binary variable due to interaction with UIR, and we were unable to converge a multivariable model with a variable to control for this interaction. However, when stratifying by detectable versus undetectable EOR-PSA, UIR had worse DMFS and PCSS among detectable EOR-PSA patients, but not undetectable patients. UIR was significant on MVA among detectable EOR-PSA patients for DMFS ( P  = 0.021) and PCSS ( P  = 0.033), while RT dose also predicted PCSS ( P  = 0.013). Conclusions EOR-PSA can assist in predicting DMFS and PCSS among UIR patients, suggesting a clinically meaningful time point for considering intensification of treatment in clinical trials of intermediate-risk men.
Jonathan Hayman, Ryan Phillips, Di Chen, Jamie Perin, Amol K. Narang, Janson Trieu, Noura Radwan, Stephen Greco, Curtiland Deville, Todd McNutt, Daniel Y. Song, Theodore L. De; Weese, Phuoc T. Tran
Wiley-Blackwell
0270-4137
02704137
1097-0045
10970045
shingle_catch_all_4 Detectable end of radiation prostate specific antigen assists in identifying men with unfavorable intermediate-risk prostate cancer at high risk of distant recurrence and cancer-specific mortality
Background Undetectable End of Radiation PSA (EOR-PSA) has been shown to predict improved survival in prostate cancer (PCa). While validating the unfavorable intermediate-risk (UIR) and favorable intermediate-risk (FIR) stratifications among Johns Hopkins PCa patients treated with radiotherapy, we examined whether EOR-PSA could further risk stratify UIR men for survival. Methods A total of 302 IR patients were identified in the Johns Hopkins PCa database (178 UIR, 124 FIR). Kaplan-Meier curves and multivariable analysis was performed via Cox regression for biochemical recurrence free survival (bRFS), distant metastasis free survival (DMFS), and overall survival (OS), while a competing risks model was used for PCa specific survival (PCSS). Among the 235 patients with known EOR-PSA values, we then stratified by EOR-PSA and performed the aforementioned analysis. Results The median follow-up time was 11.5 years (138 months). UIR was predictive of worse DMFS and PCSS ( P  = 0.008 and P  = 0.023) on multivariable analysis (MVA). Increased radiation dose was significant for improved DMFS ( P  = 0.016) on MVA. EOR-PSA was excluded from the models because it did not trend towards significance as a continuous or binary variable due to interaction with UIR, and we were unable to converge a multivariable model with a variable to control for this interaction. However, when stratifying by detectable versus undetectable EOR-PSA, UIR had worse DMFS and PCSS among detectable EOR-PSA patients, but not undetectable patients. UIR was significant on MVA among detectable EOR-PSA patients for DMFS ( P  = 0.021) and PCSS ( P  = 0.033), while RT dose also predicted PCSS ( P  = 0.013). Conclusions EOR-PSA can assist in predicting DMFS and PCSS among UIR patients, suggesting a clinically meaningful time point for considering intensification of treatment in clinical trials of intermediate-risk men.
Jonathan Hayman, Ryan Phillips, Di Chen, Jamie Perin, Amol K. Narang, Janson Trieu, Noura Radwan, Stephen Greco, Curtiland Deville, Todd McNutt, Daniel Y. Song, Theodore L. De; Weese, Phuoc T. Tran
Wiley-Blackwell
0270-4137
02704137
1097-0045
10970045
shingle_title_1 Detectable end of radiation prostate specific antigen assists in identifying men with unfavorable intermediate-risk prostate cancer at high risk of distant recurrence and cancer-specific mortality
shingle_title_2 Detectable end of radiation prostate specific antigen assists in identifying men with unfavorable intermediate-risk prostate cancer at high risk of distant recurrence and cancer-specific mortality
shingle_title_3 Detectable end of radiation prostate specific antigen assists in identifying men with unfavorable intermediate-risk prostate cancer at high risk of distant recurrence and cancer-specific mortality
shingle_title_4 Detectable end of radiation prostate specific antigen assists in identifying men with unfavorable intermediate-risk prostate cancer at high risk of distant recurrence and cancer-specific mortality
timestamp 2025-07-31T23:43:02.177Z
titel Detectable end of radiation prostate specific antigen assists in identifying men with unfavorable intermediate-risk prostate cancer at high risk of distant recurrence and cancer-specific mortality
titel_suche Detectable end of radiation prostate specific antigen assists in identifying men with unfavorable intermediate-risk prostate cancer at high risk of distant recurrence and cancer-specific mortality
topic WW-YZ
uid ipn_articles_6200611